Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Japanese (NIKKEI) Pharma Industry Analysis

UpdatedAug 10, 2026
DataAggregated Company Financials
Companies39
  • 7D2.9%
  • 3M-1.5%
  • 1Y16.1%
  • YTD-3.4%

In the last week, the Pharma industry is up 2.9%, with Chugai Pharmaceutical up 6.4%. In the last 12 months, the industry was up 16%. As for the next few years, earnings are expected to grow by 12% per annum.

Industry Valuation and Performance

Has the Japanese Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Mon, 10 Aug 2026JP¥45.3tJP¥18.1tJP¥2.1t14.7x22x2.5x
Wed, 08 Jul 2026JP¥45.6tJP¥17.5tJP¥1.9t17x24.5x2.6x
Fri, 05 Jun 2026JP¥42.9tJP¥17.5tJP¥2.2t16.1x19.4x2.5x
Sun, 03 May 2026JP¥46.7tJP¥17.4tJP¥2.2t15.7x21.5x2.7x
Tue, 31 Mar 2026JP¥50.0tJP¥17.3tJP¥2.2t16.3x22.9x2.9x
Thu, 26 Feb 2026JP¥53.4tJP¥17.3tJP¥2.2t16x24.5x3.1x
Sat, 24 Jan 2026JP¥47.9tJP¥16.9tJP¥1.9t16.6x25.1x2.8x
Mon, 22 Dec 2025JP¥45.6tJP¥16.9tJP¥1.9t16.4x24x2.7x
Wed, 19 Nov 2025JP¥44.2tJP¥16.9tJP¥1.9t15.5x23.2x2.6x
Fri, 17 Oct 2025JP¥41.7tJP¥16.8tJP¥1.8t15x22.8x2.5x
Sun, 14 Sep 2025JP¥41.5tJP¥16.8tJP¥1.8t16.3x22.7x2.5x
Tue, 12 Aug 2025JP¥39.5tJP¥16.8tJP¥1.8t15.7x21.7x2.3x
Thu, 10 Jul 2025JP¥38.8tJP¥16.8tJP¥1.8t15x22.1x2.3x
Sat, 07 Jun 2025JP¥40.3tJP¥16.8tJP¥1.8t14.3x22.8x2.4x
Mon, 05 May 2025JP¥43.0tJP¥16.7tJP¥1.7t15x25.4x2.6x
Wed, 02 Apr 2025JP¥40.1tJP¥16.5tJP¥1.5t15.2x26.7x2.4x
Fri, 28 Feb 2025JP¥40.9tJP¥16.5tJP¥1.5t15.7x27.3x2.5x
Sun, 26 Jan 2025JP¥40.7tJP¥16.1tJP¥1.4t15.5x28.9x2.5x
Tue, 24 Dec 2024JP¥41.8tJP¥16.1tJP¥1.4t15.3x29.6x2.6x
Thu, 21 Nov 2024JP¥41.9tJP¥16.1tJP¥1.4t15.1x29.6x2.6x
Sat, 19 Oct 2024JP¥44.9tJP¥15.6tJP¥1.2t15.8x37.4x2.9x
Mon, 16 Sep 2024JP¥44.1tJP¥15.5tJP¥1.2t17.6x36.7x2.8x
Wed, 14 Aug 2024JP¥44.3tJP¥15.5tJP¥1.2t16.5x36.9x2.8x
Fri, 12 Jul 2024JP¥45.6tJP¥15.0tJP¥1.1t18.9x41.6x3x
Sun, 09 Jun 2024JP¥41.2tJP¥15.0tJP¥1.1t17.9x37.6x2.7x
Tue, 07 May 2024JP¥41.3tJP¥14.9tJP¥1.3t18.8x33x2.8x
Thu, 04 Apr 2024JP¥41.2tJP¥15.1tJP¥1.2t18.9x33.9x2.7x
Sat, 02 Mar 2024JP¥43.4tJP¥15.1tJP¥1.2t20x35.7x2.9x
Mon, 29 Jan 2024JP¥40.5tJP¥15.2tJP¥1.4t20.3x29.5x2.7x
Wed, 27 Dec 2023JP¥38.7tJP¥15.2tJP¥1.4t19.3x28.1x2.6x
Fri, 24 Nov 2023JP¥39.3tJP¥15.2tJP¥1.4t20.2x28.6x2.6x
Sun, 22 Oct 2023JP¥38.7tJP¥14.9tJP¥1.4t23.3x27.1x2.6x
Tue, 19 Sep 2023JP¥41.4tJP¥14.9tJP¥1.4t24.9x29x2.8x
Thu, 17 Aug 2023JP¥40.2tJP¥14.9tJP¥1.4t22.8x28.2x2.7x
Price to Earnings Ratio

28.2x


Total Market Cap: JP¥40.2tTotal Earnings: JP¥1.4tTotal Revenue: JP¥14.9tTotal Market Cap vs Earnings and Revenue0%0%0%
Japanese Pharma Industry Price to Earnings3Y Average 28.1x202420252026
Current Industry PE
  • Investors are pessimistic on the Japanese Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 22.0x which is lower than its 3-year average PE of 28.1x.
  • The industry is trading close to its 3-year average PS ratio of 2.7x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have grown 13% per year over the last three years.
  • Revenues for these companies have grown 6.8% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Japanese Healthcare industry?

JP Market1.75%
Healthcare2.55%
Pharma2.87%
Pharma2.87%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
4519 Chugai PharmaceuticalJP¥7.11k6.4%
+JP¥699.3b		16.7%PE24.8x
4578 Otsuka HoldingsJP¥12.56k9.2%
+JP¥556.9b		60.8%PE16.3x
4568 Daiichi Sankyo CompanyJP¥2.81k9.1%
+JP¥427.8b		-21.0%PE21x
4503 Astellas PharmaJP¥2.36k8.6%
+JP¥338.6b		46.3%PE11.6x
4502 Takeda PharmaceuticalJP¥5.58k3.2%
+JP¥277.8b		30.9%PS1.9x

Latest News

4503
JP¥2,363.00
Astellas Pharma
7D
8.6%
1Y
46.3%
4568
JP¥2,805.00
Daiichi Sankyo Company
7D
9.1%
1Y
-21.0%
4506
JP¥1,345.00
Sumitomo Pharma
7D
5.9%
1Y
-0.4%
Analysis Article • Aug 09

Sumitomo Pharma's (TSE:4506) Attractive Earnings Are Not All Good News For Shareholders

We didn't see Sumitomo Pharma Co., Ltd.'s ( TSE:4506 ) stock surge when it reported robust earnings recently. We looked...
4540
JP¥3,757.00
Tsumura
7D
-0.9%
1Y
2.6%
4528
JP¥2,419.00
Ono Pharmaceutical
7D
3.5%
1Y
41.7%
4502
JP¥5,582.00
Takeda Pharmaceutical
7D
3.2%
1Y
30.9%
Narrative Update • Aug 08

4502: Orexin Launch And Biosimilar Threat Will Shape Future Returns

Analysts have raised their price target on Takeda Pharmaceutical to ¥5,600 from ¥4,900, reflecting updated assumptions around revenue growth, profit margins, and a lower future P/E multiple. What's in the News for Takeda Pharmaceutical The U.S. FDA approved Takeda Pharmaceutical's Orzeyful, or oveporexton, as the first medicine that targets the underlying orexin deficiency in narcolepsy type 1 in adults, with a controlled substance classification from the DEA still pending before U.S. launch.
4553
JP¥3,705.00
Towa Pharmaceutical
7D
-5.2%
1Y
25.8%
4554
JP¥1,824.00
Fuji Pharma
7D
-1.2%
1Y
30.6%
4548
JP¥699.00
Seikagaku
7D
-4.2%
1Y
10.1%
4507
JP¥2,842.00
Shionogi
7D
-1.9%
1Y
7.7%
Analysis Article • Aug 05

Shionogi & Co., Ltd. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Shionogi & Co., Ltd. ( TSE:4507 ) just released its first-quarter report and things are looking bullish. The company...
4523
JP¥4,949.00
Eisai
7D
6.3%
1Y
12.5%
Analysis Article • Aug 05

Results: Eisai Co., Ltd. Exceeded Expectations And The Consensus Has Updated Its Estimates

As you might know, Eisai Co., Ltd. ( TSE:4523 ) just kicked off its latest quarterly results with some very strong...
4578
JP¥12,560.00
Otsuka Holdings
7D
9.2%
1Y
60.8%
Narrative Update • Aug 05

4578: Rising Dividends And Completed Buyback Will Support A Stronger Bullish Case

The analyst price target for Otsuka Holdings has been updated from ¥13,025 to about ¥13,392, with analysts pointing to revised assumptions that combine a lower revenue growth outlook, a slightly higher projected profit margin, and a modestly adjusted future P/E multiple. What's in the News for Otsuka Holdings Otsuka Holdings has a board meeting scheduled for July 31, 2026 to review and approve a revised consolidated financial forecast for the fiscal year ending December 31, 2026, along with other agenda items.
4886
JP¥2,035.00
ASKA Pharmaceutical HoldingsLtd
7D
-4.5%
1Y
-11.6%
4519
JP¥7,112.00
Chugai Pharmaceutical
7D
6.4%
1Y
16.7%
Narrative Update • Jul 31

4519: Higher 2026 Earnings Guidance And Dividend Outlook Will Support Bullish View

Analysts have trimmed their price target for Chugai Pharmaceutical to about ¥9,687 from roughly ¥9,973, reflecting slightly lower revenue growth assumptions and a more moderate future P/E multiple while keeping expected profit margins broadly similar. What's in the News Chugai Pharmaceutical issued consolidated earnings guidance for the fiscal year ending December 31, 2026, with expected revenue of ¥1,345,000 million, Core operating profit of ¥670,000 million, Core net income of ¥485,000 million, and Core earnings per share of ¥295.00.
4887
JP¥1,596.50
Sawai Group Holdings
7D
-1.2%
1Y
-19.0%
4889
JP¥1,267.00
Renascience
7D
-15.5%
1Y
-58.9%